Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

<p>Abstract</p> <p>Background</p> <p>As a member of the TNF superfamily, TRAIL could induce human tumor cell apoptosis through its cognate death receptors DR4 or DR5, which can induce formation of the death inducing signaling complex (DISC) and activation of the membran...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Qiao Chunxia, Hu Meiyun, Guo Leiming, Lv Ming, Lin Zhou, Geng Jing, Lang Xiaoling, Li Xinying, Li Yan, Ma Yuanfang, Feng Jiannan, Shen Beifen
Formatua: Artikulua
Hizkuntza:English
Argitaratua: BMC 2012-07-01
Saila:BMC Immunology
Gaiak:
TRAIL
Death receptor 5
Monoclonal antibody
Apoptosis
Breast cancer
Sarrera elektronikoa:http://www.biomedcentral.com/1471-2172/13/40

Internet

http://www.biomedcentral.com/1471-2172/13/40

Antzeko izenburuak